Whalesbook
📉 The Financial Deep Dive
India Glycols Limited (IGL) has unveiled its strongest quarterly performance to date, alongside significant strategic strides.
The Numbers:
For the third quarter ending December 31, 2025 (Q3 FY26), IGL reported a record Net Revenue of ₹1,102 Cr, marking a robust 13.0% year-on-year (YoY) increase. EBITDA surged by 36.1% YoY to ₹176 Cr. The company's EBITDA margin expanded significantly by 277 basis points (bps) to a healthy 16.0%. Profit After Tax (PAT) also saw a healthy 18.9% YoY growth, reaching ₹68 Cr, with the PAT margin improving to 6.1% from 5.8% in the prior year.
The nine-month period (9MFY26) mirrored this strength, with Net Revenue up 11.4% YoY to ₹3,235 Cr and EBITDA increasing 28.9% YoY to ₹487 Cr. The EBITDA margin for 9MFY26 stood at 15.0%, an improvement of 208 bps.
For the full fiscal year FY25, IGL reported Net Revenue of ₹3,768 Cr (19.2% CAGR over three years) and EBITDA of ₹525 Cr (28.3% CAGR over three years), with an EBITDA margin of 13.9%. Adjusted PAT stood at ₹231 Cr (28.0% CAGR over three years) with a 6.1% margin. Key ratios for FY25 included a Debt-to-Equity ratio of 0.80x and an Interest Coverage Ratio of 2.50x. ROCE improved to 11.6%.
The Quality:
IGL has demonstrated a marked improvement in profitability quality. The expansion in EBITDA margins by 277 bps in Q3 FY26 highlights successful cost management and a favourable product mix. A substantial reduction in total debt by ₹582 Cr is a critical achievement, comprising ₹467 Cr from a preferential allotment and the remainder from internal accruals. This deleveraging is expected to lead to further interest cost savings, anticipated fully from Q4 FY26.
Segmental Performance Drivers:
The Bio-Fuel (BF) segment was a standout performer, with revenue growth of 45.2% YoY in Q3 and 51.2% YoY in 9MFY26. The Bio-Based Specialties and Performance Chemicals (BSPC) segment reported excellent EBITDA performance, driven by a strategic focus on high-margin products and effective cost actions, leading to significant EBIT margin expansion. The Potable Spirits (PS) segment also contributed positively with healthy revenue growth (up 5.0% YoY in Q3 and 16.6% YoY in 9MFY26) buoyed by new product launches and premiumisation. Conversely, the Ennature Biopharma (EB) segment faced a challenging operating environment, with revenue declining by 14.0% in 9MFY26.
Proposed Restructuring & Outlook:
IGL is making significant headway with its proposed demerger plan, aiming to create distinct entities for its Bio Pharma and Spirits & Biofuel undertakings. With No Objection/Observation Letters received from stock exchanges and approval from the National Company Law Tribunal (NCLT), the appointed date for the scheme is set for April 1, 2026. This strategic move is designed to unlock stakeholder value, enhance management focus, and optimize resource allocation.
Management remains confident in sustaining positive financial performance, supported by a diversified product portfolio, operational leverage, and a robust pipeline in performance chemicals. The anticipated reduction in interest costs from Q4 FY26 further bolsters the outlook.
🚩 Risks & Outlook:
While the overall outlook is positive, the declining revenue in the Ennature Biopharma segment warrants monitoring. Execution risks associated with the demerger, though progress is strong, remain a consideration. Investors will watch for the full realization of interest savings and the successful operationalization of the demerged entities to unlock their respective potentials.